Innovative Partnership to Transform Cancer Treatment
YAS Healthcare, a prominent provider in healthcare services, has made significant strides by signing a contract with IBA (Ion Beam Applications S.A.), a pioneer in particle accelerator technologies. This collaboration marks a pivotal moment as YAS Healthcare prepares to introduce the first ProteusONE proton therapy system in the Gulf Cooperation Council (GCC) region, specifically tailored for cancer treatment.
Establishing the First Proton Therapy Centre
The partnership aims to establish the very first operational proton therapy center within the GCC, emphasizing YAS Healthcare's commitment to elevating cancer treatment methodologies. By incorporating the state-of-the-art ProteusONE system, YAS Healthcare is set to initiate patient treatments in the foreseeable future, marking a promising milestone in medical innovation.
About the ProteusONE Solution
The ProteusONE system is recognized for its compact design and advanced capabilities, which allow it to be upgraded continuously, ensuring that patients benefit from the latest in cancer treatment technologies. The multi-year operation and maintenance agreement included in this contract aims to ensure the ongoing efficacy and reliability of the system.
Leadership Insights
Olivier Legrain, the Chief Executive Officer of IBA, expressed enthusiasm about the collaboration, highlighting the importance of making cutting-edge technology available for patients in the region. He noted that this contract showcases IBA's technological advancements and reinforces its leadership in the global market.
A Commitment to Quality Care
Dr. Mohammed Zaki, the Medical Director and General Manager of YAS Healthcare, underlined the rigorous selection process that led to this partnership with IBA. Choosing a world-class leader in proton therapy demonstrates YAS Healthcare's dedication to providing top-tier medical services in Abu Dhabi and beyond. Just five months prior, YAS Healthcare received approval from the Dubai Health Authority to establish this groundbreaking center, further solidifying their commitment to patient care and innovation.
Financial Considerations
The estimated price for the ProteusONE system, alongside a multi-year maintenance contract, falls within the range of €35 to €45 million. This investment reflects YAS Healthcare's commitment to bringing advanced medical treatment options to the region.
About IBA
IBA stands at the forefront of particle accelerator technology, serving as a leading supplier of solutions in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry. Headquartered in Louvain-la-Neuve, Belgium, IBA employs approximately 2,100 dedicated staff globally and has established itself as a certified B Corporation, adhering to rigorous standards of social and environmental performance.
About YAS Healthcare
Founded in 2014 as a subsidiary of DAS Holding, YAS Healthcare is committed to delivering exceptional healthcare services in a patient-centric environment. The institution aims to become the preferred destination for medical care through a compassionate and ethical approach to healing, pursuing medical excellence to meet patients' needs.
Frequently Asked Questions
What is the ProteusONE system?
The ProteusONE is a compact proton therapy solution designed to deliver targeted cancer treatments with a focus on patient safety and comfort.
What significant milestone has YAS Healthcare achieved?
YAS Healthcare is set to establish the first proton therapy center in the GCC region, enhancing local cancer care options.
How does IBA contribute to this partnership?
IBA provides state-of-the-art technology and expertise in proton therapy, ensuring high-quality treatment for patients at YAS Healthcare.
When is YAS Healthcare expected to begin treating patients?
The center aims to commence patient treatments in 2029, bringing advanced care to the community.
What is IBA's global significance in healthcare?
IBA is recognized as a world leader in particle accelerators and proton therapy, playing a crucial role in advancing cancer treatment technologies globally.
